| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/26/2005 | EP1203233B1 Method for identifying modulating compounds of neurotransmitters |
| 01/26/2005 | EP1131062B1 Injectable propofol formulations |
| 01/26/2005 | EP1017835A4 Methods of using cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy |
| 01/26/2005 | EP0914110B1 Method of modulating microcirculation |
| 01/26/2005 | EP0725826B1 Improvements relating to cancer therapy |
| 01/26/2005 | CN1571836A Human antibodies specific for interleukin 15 (IL-15) |
| 01/26/2005 | CN1571782A Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 01/26/2005 | CN1571675A Treatment and diagnosis of insulin-resistant states |
| 01/26/2005 | CN1571674A Use of histamine to treat liver disease |
| 01/26/2005 | CN1571673A Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents |
| 01/26/2005 | CN1571671A Drugs comprising combination of triazaspiro [5.5] undecane derivative with cytochrome p450 isozyme 3A4 inhibitor and/or P-glycoprotein inhibitor |
| 01/26/2005 | CN1571669A Novel combination |
| 01/26/2005 | CN1571668A Salts formed of an AT1-receptor antagonist and a cardiovascular agent |
| 01/26/2005 | CN1571663A Dosage forms, devices and methods of treatment |
| 01/26/2005 | CN1571662A Highly compressible ethylcellulose for tableting |
| 01/26/2005 | CN1570101A Optimized SARS coronary virus N protein gene |
| 01/26/2005 | CN1569777A Chiral source and pharmaceutical salt or complex of organic alkali drug |
| 01/26/2005 | CN1568978A Composition for preventing and treating whelk |
| 01/26/2005 | CN1186332C New thryoid receptor ligands and process II |
| 01/26/2005 | CN1186097C Pharmaceutical compositions comprising an aldose reductase inhibitor and an ACE inhibitor |
| 01/26/2005 | CN1186019C Method for increasing retinal blood flow |
| 01/26/2005 | CN1186013C Peroral medicine deliver controlled system providing temporal and spatial control |
| 01/25/2005 | US6846920 Comprises nucleotide sequences coding eosinophil protease (EOS) for preparing laundry detergents, stain-removing solutions, skin care products and treating blood and respiratory system disorders |
| 01/25/2005 | US6846907 Osteoporosis treatment |
| 01/25/2005 | US6846844 (3R)-5-((2-hydroxy-4-methylphenyl)amino)-3-methyl-5-oxo-pentan oic acid, or 3,5-dichloro derivative or salts thereof; deliver active agents to selected biological systems in increased or improved bioavailability |
| 01/25/2005 | US6846841 Anti-angiogenic compositions and methods of use |
| 01/25/2005 | US6846838 Ureido-substituted aniline compounds useful as serine protease inhibitors |
| 01/25/2005 | US6846837 Topical administration of basic antifungal compositions to treat fungal infections of the nails |
| 01/25/2005 | US6846831 Method of treating the syndrome of lipodystrophy |
| 01/25/2005 | US6846828 Aminopyrimidine and aminopyridine anti-inflammation agents |
| 01/25/2005 | US6846823 Method of treating lower urinary tract disorders |
| 01/25/2005 | US6846822 Product comprising a heterotrimeric G protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension |
| 01/25/2005 | US6846818 Selective inhibitors of cyclooxygenase-2 |
| 01/25/2005 | US6846816 Combinations of drugs for the treatment of neoplastic disorders |
| 01/25/2005 | US6846805 Oligopeptides or polypeptides used to inhibit transmembrane proteases such as aspartyl secretases, administered for prophylaxis of neurodegenerative diseases; Alzheimer's disease |
| 01/25/2005 | US6846802 Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties |
| 01/25/2005 | US6846799 Administering epidermal growth factor antagonist; blocking with antibody; chronic obstructive pulmonary disease |
| 01/25/2005 | US6846674 Gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor, of the signal transduction pathway is modified resulting in a modified AP-1 activity and |
| 01/25/2005 | US6846670 Expressing heterologous nucleotide sequences in cells; obtain vascular cells, incubate with herpes virus, monitor propagation of virus in central nervous system |
| 01/25/2005 | US6845777 Composition to reduce or quit smoking addiction |
| 01/25/2005 | CA2388674C Inhibitors of endo-exonuclease activity for treating cancer |
| 01/25/2005 | CA2354695C Compositions and methods for amelioration of human female sexual dysfunction |
| 01/25/2005 | CA2179377C Method of treatment of hormone-unresponsive metastatic prostate cancer |
| 01/21/2005 | CA2435196A1 Radical and etiological method of treatment for premature wrinkles and aging |
| 01/20/2005 | WO2005004988A2 Compositions and methods relating to novel compounds and targets thereof |
| 01/20/2005 | WO2005004942A2 Injectable composite for the magnetocytolysis of bone metastatic cells |
| 01/20/2005 | WO2005004915A2 Compositions comprising meloxicam |
| 01/20/2005 | WO2005004914A1 MEDICINAL COMPOSITION CONTAINING NF-κB DECOY FOR TREATING AND PREVENTING RESPIRATORY DISEASES AND METHOD OF USING THE SAME |
| 01/20/2005 | WO2005004913A1 Pharmaceutical composition containing decoy and method of using the same |
| 01/20/2005 | WO2005004906A2 Use of dp iv and apn inhibitors for the treatment of dermatological diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts |
| 01/20/2005 | WO2005004896A1 Nop receptor antagonists for the treatment of parkinson’s disease |
| 01/20/2005 | WO2005004893A2 Inhibition of stress-induced ligand-dependent egfr activation |
| 01/20/2005 | WO2005004880A1 Vaginal compositions for treating pelvic tissue infections and traumas |
| 01/20/2005 | WO2005004873A1 Use of antivirals against inflammatory bowel diseases |
| 01/20/2005 | WO2005004869A1 Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| 01/20/2005 | WO2005004856A1 Antifungal composition |
| 01/20/2005 | WO2005004829A1 Powdery compositions and skin preparation containing the same for external use |
| 01/20/2005 | WO2005004781A1 Non-invasive intravascular thrombolyisis using modified ultrasound techniques |
| 01/20/2005 | WO2004106411A3 Biodegradable poly(beta-amino esters) and uses thereof |
| 01/20/2005 | WO2004100992A3 Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| 01/20/2005 | WO2004098641A3 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 01/20/2005 | WO2004096194A9 Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft domains |
| 01/20/2005 | WO2004089407A3 Zwitterionic immunomodulators for the treatment of asthma and allergy |
| 01/20/2005 | WO2004089355A3 Compositions for treating microbial and parasitic infections in cattle and other animals |
| 01/20/2005 | WO2004087209A9 Preparation for sustaining therapeutically effective blood concentration of analgesic activity potentiator |
| 01/20/2005 | WO2004083382A3 Compositions and methods for treating hyperimmune response in the eye |
| 01/20/2005 | WO2004082595A3 Therapeutic use of tumor necrosis factor-alpha mutein |
| 01/20/2005 | WO2004080467A3 Method of treating and preventing hyperparathyroidism with vitamin d2 or d4 compounds |
| 01/20/2005 | WO2004078139A3 Therapeutic compositions |
| 01/20/2005 | WO2004069213A3 Cosmetic composition comprising a 2-alkylideneaminooxyacetamide |
| 01/20/2005 | WO2004066940A3 Compositions and methods containing substituted quinolines and substituted diphenylsulfones |
| 01/20/2005 | WO2004012791A3 Improved injection system |
| 01/20/2005 | WO2003099762A8 Agents and methods for the treatment of disorders associated with oxidative stress |
| 01/20/2005 | WO2003062392A3 Methods of treating conditions associated with an edg receptor |
| 01/20/2005 | WO2003035848A9 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer |
| 01/20/2005 | US20050015820 Using transgenic mouse tissue as model for monitoring agents that affect appetite, energy expenditure and caloric and food intake; dietetics and weight gain |
| 01/20/2005 | US20050014848 Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors |
| 01/20/2005 | US20050014847 Ambroxol for the treatment of chronic nociceptive pain |
| 01/20/2005 | US20050014846 Oral administration, bioavailability; no central nervous and cardiovascular side effects |
| 01/20/2005 | US20050014845 Oral administration, bioavailability; no central nervous and cardiovascular side effects |
| 01/20/2005 | US20050014844 Oral administration; bioavailability; no central nervous system or cardiovascular side effects |
| 01/20/2005 | US20050014843 Utilizing tomoxetine compound or such as n-ethyl-3-phenyl-3-(2-butylthiophenoxy)propyl-amine; attention deficit, hyperactivity, involuntary repetitive movement or sound disorders, tourette's syndrome |
| 01/20/2005 | US20050014834 Selective anesthetic agents and methods of identifying the same |
| 01/20/2005 | US20050014827 Formulations containing polyphenol derivatives; food and feed supplements; bactericidal, fungicidal and virucidal effects |
| 01/20/2005 | US20050014808 Combined agents for treatment of glaucoma |
| 01/20/2005 | US20050014807 Therapeutic compounds for treating dyslipidemic conditions |
| 01/20/2005 | US20050014801 Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use |
| 01/20/2005 | US20050014799 In mixture with enzyme inhibitors and other active materials |
| 01/20/2005 | US20050014797 Compositions and methods to treat gastrointestinal disorders |
| 01/20/2005 | US20050014776 Steroidal compounds for inhibiting steroid sulphatase |
| 01/20/2005 | US20050014770 Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
| 01/20/2005 | US20050014762 Combination |
| 01/20/2005 | US20050014743 Synergistic mixture; antidepressants; multiple sclerosis; Parkinson's disease; Alzheimer's disease; antitumor agents; sleep disorders; glandular disorders |
| 01/20/2005 | US20050014736 Composition comprising progesterone-receptor antagonists and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| 01/20/2005 | US20050014729 Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| 01/20/2005 | US20050014726 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
| 01/20/2005 | US20050014715 Inosine compounds and their use for treating or preventing an inflammation or reperfusion disease |
| 01/20/2005 | US20050014711 Using oligonucleotide antibody |
| 01/20/2005 | US20050014703 Cell differentiation, regeneration of epithelium pancreas cells into insulin producing beta-cells; administrering a peptidyl- peptidase activator |
| 01/20/2005 | US20050014699 Combinations of enzyme inhibitor-containing preparations and the use thereof |